Skip to Main Content

Paper Details

Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma.
Eur Urol Oncol
32
2022
Nonmetastatic Renal Cell Carcinoma, PATIENT, PD-1, Patients, RCC, fatigue, nonmetastatic, nonmetastatic renal cell carcinoma, patients, programmed cell death protein 1, pruritis, rash, renal cell carcinoma, tumor
Author NameAffiliation
Bruce J TrockThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine
Phillip M PierorazioThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center
Tamara L LotanJohns Hopkins University School of Medicine
  • 1 - 3

Datasets

Release 1.2